Shiyao Group (01093): Shiyao Innovation's mid-term net profit of 1,18-1.36 billion yuan is expected to turn a year-on-year loss into profit

Zhitongcaijing · 3d ago

According to Zhitong Finance App News, Shiyao Group (01093) released the performance forecast of Shiyao Innovative Pharmaceutical Co., Ltd. for the six months ending June 30, 2026. The net profit attributable to shareholders of listed companies from January 1, 2026 to June 30, 2026 is expected to be RMB 1,18-1.36 billion, and a net loss attributable to shareholders of listed companies of RMB 27.461 million during the same period last year.

During the reporting period, the company continued to increase investment in R&D and innovation, focusing on cutting-edge technology platforms such as antibody drugs, ADC and mRNA vaccines, and steadily advancing the R&D and industrialization process of the biopharmaceutical business pipeline. The product layout covered various core treatment fields such as tumors, metabolic and autoimmune diseases.